Marlin G E, Davis P R, Rutland J, Berend N
Thorax. 1980 Jun;35(6):441-5. doi: 10.1136/thx.35.6.441.
Plasma and sputum concentrations of erythromycin were measured in 10 patients with chronic bronchitis during an eight-day course of a new formulation of erythromycin stearate. The plasma erythromycin levels compared favourably with the minimal inhibitory concentrations for common respiratory pathogens and indicated adequate gastrointestinal absorption when the drug was taken immediately before food. Sputum erythromycin levels were variable and in some patients low or undetectable. Measurable sputum erythromycin levels were approximately 10% of plasma levels with no evidence of accumulation and were of similar order of magnitude to the minimal inhibitory concentrations for common respiratory pathogens except Haemophilus influenzae. There was no correlation between sputum and plasma erythromycin levels. There was a trend for higher erythromycin levels in sputum containing increasing amounts of pus and also when plasma levels increased.
在10例慢性支气管炎患者服用新剂型硬脂酸红霉素的8天疗程中,测定了血浆和痰液中红霉素的浓度。血浆红霉素水平与常见呼吸道病原体的最低抑菌浓度相比具有优势,且表明在饭前立即服药时胃肠道吸收良好。痰液中红霉素水平各不相同,部分患者较低或检测不到。可测得的痰液红霉素水平约为血浆水平的10%,无蓄积迹象,且与除流感嗜血杆菌外的常见呼吸道病原体的最低抑菌浓度处于相似数量级。痰液和血浆中红霉素水平之间无相关性。痰液中红霉素水平有随脓液量增加以及血浆水平升高而升高的趋势。